Enanta Pharmaceuticals, Inc.
ENTA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.45 | 0.11 | -1.37 | 0.06 |
| FCF Yield | 0.00% | 10.76% | -13.60% | -20.92% |
| EV / EBITDA | -26.08 | -21.01 | -13.02 | -13.05 |
| Quality | ||||
| ROIC | -6.92% | -6.60% | -7.48% | -6.93% |
| Gross Margin | 0.00% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | -0.96 | 0.60 | 0.75 | 0.36 |
| Growth | ||||
| Revenue 3-Year CAGR | -6.22% | -7.01% | -7.40% | -6.74% |
| Free Cash Flow Growth | 0.00% | 208.27% | 37.27% | -32.01% |
| Safety | ||||
| Net Debt / EBITDA | -10.37 | -10.54 | -7.41 | -6.90 |
| Interest Coverage | -7.70 | -11.68 | -14.31 | -12.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 40.95 | 41.07 | 244.98 | 213.14 |